Walter and Eliza Hall Institute

Cancer blood test trialed to prevent unnecessary chemo

Embargoed until: Publicly released:

Cancer patients could be spared unnecessary chemotherapy – and its side effects – by a new blood test that is in clinical trials at more than 40 hospitals in Australia and New Zealand. The trials, led by Melbourne researchers, are investigating whether patients can be assessed after cancer surgery using a simple blood test to determine whether they need chemotherapy or not. Results from the same test could also help to scale the dose for the patients who do need chemotherapy, depending on their risk of cancer returning.

Organisation/s: Walter and Eliza Hall Institute of Medical Research (WEHI)

Funder: The Marcus Foundation (US), the Australian Government National Health and Medical Research Council, the Victorian Cancer Agency and the Victorian Government.

Media Release

From: Walter and Eliza Hall Institute of Medical Research (WEHI)

Cancer blood test trialed to prevent unnecessary chemo

Cancer patients could be spared unnecessary chemotherapy – and its side effects – by a new blood test that is in clinical trials at more than 40 hospitals in Australia and New Zealand.

The trials, led by Melbourne researchers, are investigating whether patients can be assessed after cancer surgery using a simple blood test to determine whether they need chemotherapy or not. Results from the same test could also help to scale the dose for the patients who do need chemotherapy, depending on their risk of cancer returning.

Currently many early stage cancer patients who have surgical treatment also receive chemotherapy as a precaution because there is no reliable way to know which patients will have their cancer return after surgery.

In many cases, patients are receiving unnecessary chemotherapy, said the trial lead, Associate Professor Jeanne Tie, who is a clinician scientist at the Walter and Eliza Hall Institute and a medical oncologist at the Peter MacCallum Cancer Centre and Western Health.

“While chemotherapy is an essential, life-saving treatment, we don’t want patients receiving it if they don’t need it. We want to help these patients avoid serious and ongoing side-effects associated with chemotherapy,” she said.

Associate Professor Tie said the trials would test whether the ‘circulating tumour DNA (ctDNA) test’ could reliably indicate to an oncologist whether or not a patient needed to start chemotherapy after their cancer had been surgically removed, to give the best chance of preventing recurrence.

“We would like to be able to tell some patients that they can safely avoid chemotherapy because their cancer is unlikely to recur. For patients who are at a high risk of recurrence, we want to be able to give them a more intensive dose of chemotherapy than those with a lower risk of recurrence,” she said.

In the short term, people who are receiving chemotherapy may experience  a range of side-effects including pain, fatigue, nausea and other digestive issues, bleeding problems and an increased susceptibility to infection. Long term side-effects of chemotherapy may include heart, lung, nerve and memory problems, and fertility issues.

The ctDNA test looks for fragments of tumour DNA in a patient’s blood after the tumour has been surgically removed. The trial is determining whether the amount of ctDNA in a patient’s blood indicates their risk of relapse – patients at the highest risk can be treated aggressively with chemotherapy, while patients with no detectable ctDNA in their blood are at low risk of cancer recurrence and may not need chemotherapy. The ctDNA blood test was developed through a collaboration between the Walter and Eliza Hall Institute and Johns Hopkins Kimmel Cancer Centre, US.

The trial began in early stage bowel cancer patients in 2015 and has already shown it can determine whether these patients can be divided into ‘high risk’ and ‘low risk’ groups. The trial was extended to women with ovarian cancer in 2017.

The ovarian cancer arm of the trial is led by Walter and Eliza Hall Institute clinician-researcher Associate Professor Sumi Ananda, who is also medical oncologist at the Peter MacCallum Cancer Centre and Western Health.

“We suspect that many women with early stage ovarian cancer can be treated with surgery alone, but we currently treat all these patients as though their cancer may recur, with high dose chemotherapy,” she said.

“Undergoing chemotherapy is a huge imposition on a patient’s life, both because of the side effects patients have to endure, as well as the time the treatment takes. Many of my patients have to stop working, and postpone important parts of their life such as travel, so they can attend their chemotherapy sessions and manage the side effects of the treatment.”

“In the future I hope that we can safely and accurately determine which patients can avoid chemotherapy – for these people it will be a huge improvement on their quality of life. I also hope that by identifying patients with the highest risk of recurrence, we can give them intensive chemotherapy to give them the best chance of survival. This test could be an important step towards personalising cancer treatment for individual patients,” Associate Professor Ananda said.

Trial participant Professor Hugh McDermott said that receiving a 'low risk' ctDNA test result provided him with peace of mind after having surgery for bowel cancer last year.

"The test indicated that my cancer was unlikely to recur, meaning I didn't need to have chemotherapy," he said. "Avoiding the potential side-effects and inconvenience of chemotherapy was a huge relief – it meant I could get back to work quickly and continue to enjoy travel and social events. This test could potentially be enormously beneficial not only for patients and their doctors, but also for their family, friends, and carers."

More than 400 patients have already joined in the trials of the ctDNA test (DYNAMIC), but the lead researchers hope to recruit 2000 participants. More than 40 hospitals across all states in Australia and in New Zealand are participating in the trial, making it one of the largest trials in Australia and internationally to investigate a predictive blood test to guide cancer treatment. The trials are expected to run until 2021 for bowel cancer and 2019 for ovarian cancer.

The research was funded by the Marcus Foundation (US), the Australian Government National Health and Medical Research Council, the Victorian Cancer Agency and the Victorian Government. The bowel cancer trials are endorsed by the Australasian Gastro-Intestinal Trials Group; the ovarian cancer trial is endorsed by the Australia New Zealand Gynaecological Oncology Group.

The Walter and Eliza Hall Institute, the Peter MacCallum Cancer Centre, and Western Health are partners in the Victorian Comprehensive Cancer Centre alliance.

Attachments:

  • Walter and Eliza Hall Institute of Medical Research (WEHI)
    Web page
    Includes information about how to join the trial and participating centres

News for:

Australia
New Zealand
International
VIC

Multimedia:

  • Measuring recurrence risk with the circulating tumour DNA test
    Measuring recurrence risk with the circulating tumour DNA test

    Researchers at the Walter and Eliza Hall Institute, in collaboration with Johns Hopkins University, have developed a blood test that can detect tumour DNA in a cancer patient's blood. The test, called the circulating tumour DNA (ctDNA) test, is in clinical trials to determine whether it can be used to guide a patient's treatment decisions. Patients with low ctDNA are able to avoid chemotherapy and its harmful side effects, while patients with the highest ctDNA levels are given intensive chemotherapy to give them the best chance of survival.

    File size: 639.2 KB

    Attribution: Walter and Eliza Hall Institute, Australia

    Permission category: Free to share or modify (must credit)

    Last modified: 18 Oct 2018 12:05am

    NOTE: High resolution files can only be downloaded here by registered journalists who are logged in.

  • Cancer blood test trialed to prevent unnecessary chemo

    Medical oncologists Associate Professors Jeanne Tie and Sumi Ananda, and trial participant Anne, discuss a clinical trial of a blood test that indicates a patient's risk of cancer recurrence after surgery. The trials are running at more than 40 hospitals in Australia and New Zealand.

    File Size: 29.2 MB

    Attribution: Walter and Eliza Hall Institute

    Permission Category: Free to share or modify (must credit)

    Last Modified: 17 Oct 2018 12:17am

    Note: High resolution video files are only available for download here by registered journalists who are logged in.

  • Circulating tumour DNA test
    Circulating tumour DNA test

    The circulating tumour DNA (ctDNA) test uses a blood test to detect tumour DNA in a cancer patient's blood. A clinical trial in Australia and New Zealand is investigating whether this test can be used to assess a patient's risk of cancer recurrence after surgery. The ctDNA blood test was developed through a collaboration between the Walter and Eliza Hall Institute and Johns Hopkins Kimmel Cancer Centre, US.

    File size: 610.4 KB

    Attribution: Walter and Eliza Hall Institute, Australia

    Permission category: Free to share or modify (must credit)

    Last modified: 18 Oct 2018 12:03am

    NOTE: High resolution files can only be downloaded here by registered journalists who are logged in.

  • Circulating tumour DNA test trial leaders
    Circulating tumour DNA test trial leaders

    A trial of a new blood test that predicts cancer recurrence is being led by Associate Professor Sumi Ananda (L) and Associate Professor Jeaane Tie , who are both clinician scientists at the Walter and Eliza Hall Institute, and medical oncologists at the Peter Mac and Western Health.

    File size: 252.8 KB

    Attribution: Walter and Eliza Hall Institute, Australia

    Permission category: Free to share or modify (must credit)

    Last modified: 18 Oct 2018 12:01am

    NOTE: High resolution files can only be downloaded here by registered journalists who are logged in.

  • DNA strands
    DNA strands

    A new clinical trial running in all states in Australia and in New Zealand is using a blood test to measure the amount of cancer DNA in a patient's blood after they have their tumour surgically removed. The trial is led by clinician-scientists at Melbourne's Walter and Eliza Hall Institute who have clinical appointments at Peter Mac and Western Health.

    File size: 1.7 MB

    Attribution: Walter and Eliza Hall Institute, Australia

    Permission category: Free to share or modify (must credit)

    Last modified: 18 Oct 2018 12:04am

    NOTE: High resolution files can only be downloaded here by registered journalists who are logged in.

  • Circulating tumour DNA test trial leaders
    Circulating tumour DNA test trial leaders

    A trial of a new blood test that predicts cancer recurrence is being led by Associate Professor Sumi Ananda (R) and Associate Professor Jeaane Tie , who are both clinician scientists at the Walter and Eliza Hall Institute, and medical oncologists at the Peter Mac and Western Health.

    File size: 722.5 KB

    Attribution: Walter and Eliza Hall Institute, Australia

    Permission category: Free to share or modify (must credit)

    Last modified: 18 Oct 2018 12:00am

    NOTE: High resolution files can only be downloaded here by registered journalists who are logged in.

  • Circulating tumour DNA test trial leaders
    Circulating tumour DNA test trial leaders

    A trial of a new blood test that predicts cancer recurrence is being led by Associate Professor Jeaane Tie (L) and Associate Professor Sumi Ananda, who are both clinician scientists at the Walter and Eliza Hall Institute, and medical oncologists at the Peter Mac and Western Health.

    File size: 1.0 MB

    Attribution: Walter and Eliza Hall Institute, Australia

    Permission category: Free to share or modify (must credit)

    Last modified: 18 Oct 2018 12:01am

    NOTE: High resolution files can only be downloaded here by registered journalists who are logged in.

Show less
Show more

Media contact details for this story are only visible to registered journalists.